NuCana (NASDAQ:NCNA) Trading Down 4.8% – Should You Sell?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s stock price fell 4.8% during mid-day trading on Tuesday . The company traded as low as $2.89 and last traded at $2.95. 76,073 shares changed hands during mid-day trading, a decline of 3% from the average session volume of 78,638 shares. The stock had previously closed at $3.10.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NCNA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Thursday, January 22nd. Wall Street Zen raised NuCana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

NuCana Stock Down 4.8%

The company has a market capitalization of $88,500.00, a P/E ratio of -0.02 and a beta of 1.60. The business has a fifty day moving average price of $3.61 and a 200 day moving average price of $4.77.

NuCana (NASDAQ:NCNA) last announced its earnings results on Thursday, November 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.69) by $2.59. As a group, equities analysts forecast that NuCana PLC Sponsored ADR will post -13.42 earnings per share for the current year.

Institutional Trading of NuCana

A hedge fund recently raised its stake in NuCana stock. FNY Investment Advisers LLC increased its holdings in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 as of its most recent SEC filing. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.